The complement system: a novel therapeutic target for age-related macular degeneration

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014;2(2):e106–116. doi: 10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophtalmol. 2000;118(1):47–51. doi: 10.1001/archopht.118.1.47
   PubMedGoogle Scholar
• Williams RA, Brody BL, Thomas RG, et al. The psychosocial impact of macular degeneration. Arch Ophtalmol. 1998;116(4):514–520. doi: 10.1001/archopht.116.4.514
   PubMed Web of Science ®Google Scholar
• Spooner KL, Mhlanga CT, Hong TH, et al. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–2491. doi: 10.2147/OPTH.S185052
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Stein JD, et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Canadian Journal Of Ophthalmology. 2005;40(3):277–287. doi: 10.1016/S0008-4182(05)80070-5
   PubMed Web of Science ®Google Scholar
• Hernandez Trillo A, Dickinson CM. The impact of visual and nonvisual factors on quality of life and adaptation in adults with visual impairment. Invest Ophthalmol Visual Sci. 2012;53(7):4234–4241. doi: 10.1167/iovs.12-9580
   PubMed Web of Science ®Google Scholar
• Mangione CM, Gutierrez PR, Lowe G, et al. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol. 1999;128(1):45–53. doi: 10.1016/S0002-9394(99)00169-5
   PubMed Web of Science ®Google Scholar
• Wang L, Clark ME, Crossman DK, et al. Abundant lipid and protein components of Drusen. PLoS One. 2010;5(4):e10329. doi: 10.1371/journal.pone.0010329
   PubMed Web of Science ®Google Scholar
• Schatz H, McDonald HR. Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss. Ophthalmol. 1989;96(10):1541–1551. doi: 10.1016/S0161-6420(89)32694-7
   PubMed Web of Science ®Google Scholar
• Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye. 1988;2(5):552–577. doi: 10.1038/eye.1988.106
   PubMed Web of Science ®Google Scholar
• Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2004;44(4):17. doi: 10.1097/00004397-200404440-00004
   PubMedGoogle Scholar
• Tielsch JM, Javitt JC, Coleman A, et al. The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N Engl J Med. 1995;332(18):1205–1209. doi: 10.1056/NEJM199505043321806
   PubMed Web of Science ®Google Scholar
• Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye. 2017;31(1):1–9. doi: 10.1038/eye.2016.208
   PubMed Web of Science ®Google Scholar
• Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers 2021. 2021;7(1):1–25. doi: 10.1038/s41572-021-00265-2
   PubMed Web of Science ®Google Scholar
• Shughoury A, Sevgi DD, Ciulla TA. Molecular genetic mechanisms in age-related macular degeneration. Genes. 2022;13(7):1233. doi: 10.3390/genes13071233
   PubMed Web of Science ®Google Scholar
• Datta S, Cano M, Ebrahimi K, et al. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017;60:201–218. doi: 10.1016/j.preteyeres.2017.03.002
   PubMed Web of Science ®Google Scholar
• Beatty S, Koh HH, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115–134. doi: 10.1016/S0039-6257(00)00140-5
   PubMed Web of Science ®Google Scholar
• Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010;29(2):95–112. doi: 10.1016/j.preteyeres.2009.11.003
   PubMed Web of Science ®Google Scholar
• Whitmore SS, Sohn EH, Chirco KR, et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res. 2015;45:1–29. doi: 10.1016/j.preteyeres.2014.11.005
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296(5566):298–300. doi: 10.1126/science.1068883
   PubMed Web of Science ®Google Scholar
• Mukai R, Okunuki Y, Husain D, et al. The complement system is critical in maintaining retinal integrity during aging. Front Aging Neurosci. 2018;10:15. doi: 10.3389/fnagi.2018.00015
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9(10):729–740. doi: 10.1038/nri2620
   PubMed Web of Science ®Google Scholar
• Reid KBM. Complement component C1q: historical perspective of a functionally versatile, and structurally unusual, serum protein. Front Immunol. 2018;9:764. doi: 10.3389/fimmu.2018.00764
   PubMed Web of Science ®Google Scholar
• Yednock T, Fong DS, Lad EM. C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration. Int J Retin Vitr. 2022;8(1):1–14. doi: 10.1186/s40942-022-00431-y
   PubMedGoogle Scholar
• Garred P, Genster N, Pilely K, et al. A journey through the lectin pathway of complement—MBL and beyond. Immunol Rev. 2016;274(1):74–97. doi: 10.1111/imr.12468
   PubMed Web of Science ®Google Scholar
• Hugli TE, Müller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol. 1978;26:1–53.
   PubMedGoogle Scholar
• Ehlenberger AG, Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med. 1977;145(2):357–371. doi: 10.1084/jem.145.2.357
   PubMed Web of Science ®Google Scholar
• Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology. 2016;221(6):747–751. doi: 10.1016/j.imbio.2015.04.006
   PubMed Web of Science ®Google Scholar
• Müller-Eberhard HJ, Schreiber RD. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol. 1980;29:1–53.
   PubMedGoogle Scholar
• Zipfel PF, Mihlan M, Skerka C. The alternative pathway of complement: a pattern recognition system. In: Lambris J, editor. Current topics in innate immunity. New York (NY): Springer; 2007. p. 80–92. doi: 10.1007/978-0-387-71767-8_7
   Google Scholar
• Harboe M, Ulvund G, Vien L, et al. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138(3):439–446. doi: 10.1111/j.1365-2249.2004.02627.x
   PubMed Web of Science ®Google Scholar
• Ferreira VP, Pangburn MK, Cortés C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 2010;47(13):2187–2197. doi: 10.1016/j.molimm.2010.05.007
   PubMed Web of Science ®Google Scholar
• Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705–732. doi: 10.1016/S1350-9462(01)00010-6
   PubMed Web of Science ®Google Scholar
• Katschke KJ, Xi H, Cox C, et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Sci Rep. 2018;8(1):7348. doi: 10.1038/s41598-018-25557-8
   PubMedGoogle Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389. doi: 10.1126/science.1109557
   PubMed Web of Science ®Google Scholar
• Tzoumas N, Hallam D, Harris CL, et al. Revisiting the role of factor H in age-related macular degeneration: insights from complement-mediated renal disease and rare genetic variants. Surv Ophthalmol. 2021;66(2):378–401. doi: 10.1016/j.survophthal.2020.10.008
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Fariss RN, Stambolian D, et al. Age-related macular degeneration: genetics and biology coming together. Ann Rev Genomics Hum Genet. 2014;15(1):151–171. doi: 10.1146/annurev-genom-090413-025610
   PubMedGoogle Scholar
• Kassa E, Ciulla TA, Hussain RM, et al. Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019;19(4):335–342. doi: 10.1080/14712598.2019.1575358
   PubMed Web of Science ®Google Scholar
• Kim BJ, Mastellos DC, Li Y, et al. Targeting complement components C3 and C5 for the retina: key concepts and lingering questions. Prog Retin Eye Res. 2021;83:100936. doi: 10.1016/j.preteyeres.2020.100936
   PubMed Web of Science ®Google Scholar
• Thakkinstian A, McKay GJ, McEvoy M, et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173(12):1365–1379. doi: 10.1093/aje/kwr025
   PubMed Web of Science ®Google Scholar
• Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized Phase 2 trial. Ophthalmol. 2020;127(2):186–195. doi: 10.1016/j.ophtha.2019.07.011
   PubMed Web of Science ®Google Scholar
• Scholl HPN. Complement inhibition in age-related macular degeneration—treat early! JAMA Ophthalmol. 2022;140(3):250–251. doi: 10.1001/jamaophthalmol.2021.6068
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing new-onset exudation in the randomized Phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy. Ophthalmology. 2021;128(9):1325–1336. doi: 10.1016/j.ophtha.2021.02.025
   PubMed Web of Science ®Google Scholar
• Shi Y, Motulsky EH, Goldhardt R, et al. Predictive value of the OCT Double-layer sign for identifying subclinical neovascularization in age-related macular degeneration. Oph Retina. 2019;3(3):211–219. doi: 10.1016/j.oret.2018.10.012
   PubMedGoogle Scholar
• Fouad YA, Santina A, Bousquet E, et al. Pathways of fluid leakage in age-related macular degeneration. Retina. 2023;43(6):873. doi: 10.1097/IAE.0000000000003798
   PubMed Web of Science ®Google Scholar
• Goldberg R, Heier JS, Wykoff CC, et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Invest Ophthalmol Visual Sci. 2022;63:1500.
   Web of Science ®Google Scholar
• Apellis Pharmaceuticals, Inc. Apellis announces 24-month results showing increased effects over time with pegcetacoplan in Phase 3 DERBY and OAKS studies in geographic atrophy (GA) [Internet]. Apellis. 2022 [cited 2023 Mar 2]. Available from: https://investors.apellis.com/news-releases/news-release-details/apellis-announces-24-month-results-showing-increased-effects
   Google Scholar
• Apellis Pharmaceuticals, Inc. Apellis presents Phase 3 functional analyses of SYFOVRETM (pegcetacoplan injection) for geographic atrophy - apellis Pharmaceuticals, Inc [Interne] Apellis Pharm. 2023 [cited 2023 Apr 29]. Available from: https://investors.apellis.com/news-releases/news-release-details/apellis-presents-phase-3-functional-analyses-syfovretm
   Google Scholar
• Apellis Pharmaceuticals, Inc. Apellis provides updates on injection kits and rare safety events with SYFOVRE® (pegcetacoplan injection) - apellis Pharmaceuticals, Inc [Internet]. Apellis Pharm. 2023 [cited 2023 Aug 31]. Available from: https://investors.apellis.com/news-releases/news-release-details/apellis-provides-updates-injection-kits-and-rare-safety-events
   Google Scholar
• Wykoff CC, Hershberger V, Eichenbaum D, et al. Inhibition of complement factor 3 in geographic atrophy with NGM621: phase 1 dose-escalation study results. Am J Ophthalmol. 2022;235:131–142. doi: 10.1016/j.ajo.2021.08.018
   PubMed Web of Science ®Google Scholar
• NGM Biopharmaceuticals, Inc. NGM bio announces topline results from the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration [Internet]. NGM Bio. 2022 [cited 2023 Feb 28]. Available from: https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-topline-results-catalina-phase-2-trial-ngm621/
   Google Scholar
• NGM Biopharmaceuticals, Inc. NGM bio announces presentation of post-hoc analyses from CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the retina society annual scientific meeting [Internet]. NGM Bio. 2022 [cited 2023 Feb 28]. Available from: https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-presentation-post-hoc-analyses-catalina-phase/
   Google Scholar
• Chung ED (Philip), Kim D, Ryu S, et al. KNP-301, a dual inhibitor of the complement pathway and angiogenesis, effectively suppresses angiogenesis and atrophy. Invest Ophthalmol Visual Sci. 2021;62:183. (Philip).
   Web of Science ®Google Scholar
• Blouse GE. CB 2782-PEG: a complement factor C3- inactivating protease and potential long-acting treatment for dry AMD [Internet]. 2019 [cited 2023 Feb 25]. Available from: https://www.catalystbiosciences.com/wp-content/uploads/2021/05/Blouse_CBDD_20191115_vF.pdf
   Google Scholar
• Anderson DH, Mullins RF, Hageman GS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134(3):411–431. doi: 10.1016/S0002-9394(02)01624-0
   PubMed Web of Science ®Google Scholar
• Johnson LV, Ozaki S, Staples MK, et al. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70(4):441–449. doi: 10.1006/exer.1999.0798
   PubMed Web of Science ®Google Scholar
• Scholl HPN, Issa PC, Walier M, et al. Correction: systemic complement activation in age-related macular degeneration. PLoS One. 2008;3(7):1–7. doi: 10.1371/annotation/32b9bc31-ed6d-4d31-9ce0-480407017bad
   Web of Science ®Google Scholar
• Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103(7):2328–2333. doi: 10.1073/pnas.0408835103
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, de AG Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693–701. doi: 10.1016/j.ophtha.2013.09.044
   PubMed Web of Science ®Google Scholar
• Roguska M, Splawski I, Diefenbach-Streiber B, et al. Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration. Invest Ophthalmol Visual Sci. 2014;55:3433.
   Web of Science ®Google Scholar
• Sherrer K, Kahl K. Anti-complement C5 monotherapy ineffective in reducing geographic atrophy lesion size. Ocular Surg News [Internet]. 2016 Feb 15 [cited 2023 Apr 29]. Available from: https://www.healio.com/news/ophthalmology/20160215/anticomplement-c5-monotherapy-ineffective-in-reducing-geographic-atrophy-lesion-size
   Google Scholar
• Gallemore RP, Elman MJ, Milton M, et al. A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age realted macular degeneration (nAMD). Invest Ophthalmol Visual Sci. 2016;57:4986.
   Web of Science ®Google Scholar
• Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal Phase 2/3 trial. Ophthalmol. 2021;128(4):576–586. doi: 10.1016/j.ophtha.2020.08.027
   PubMed Web of Science ®Google Scholar
• Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye. 2023;1–7.
   PubMed Web of Science ®Google Scholar
• Iveric Bio, Inc. Iveric bio announces positive topline data from Zimura® GATHER2 Phase 3 clinical trial in geographic atrophy [Internet]. Iveric Bio. 2022 [cited 2023 Feb 28]. Available from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-announces-positive-topline-data-zimurar-gather2-phase
   Google Scholar
• Danzig CJ, Kaiser P, Lally D, et al. Treatment response to avacincaptad pegol by baseline patient characteristics: a prespecified subgroup analysis of the phase 3 GATHER2 study. Invest Ophthalmol Visual Sci. 2023;64:984.
   Web of Science ®Google Scholar
• Iveric Bio, Inc. Iveric bio announces vision loss reduction data in geographic atrophy from avacincaptad pegol GATHER trials [Internet]. Business Wire. 2023 [cited 2023 Aug 20]. Available from: https://www.businesswire.com/news/home/20230228006487/en/Iveric-Bio-Announces-Vision-Loss-Reduction-Data-in-Geographic-Atrophy-from-Avacincaptad-Pegol-GATHER-Trials
   Google Scholar
• Astellas Pharma. Iveric Bio Receives U.S. FDA approval for IZERVAYTM (avacincaptad pegol intravitreal solution), a New treatment for geographic atrophy [Internet]. Astellas. 2023 [cited 2023 Aug 26]. Available from: https://www.astellas.com/en/news/28281
   Google Scholar
• Kumar-Singh R. The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials. Exp Eye Res. 2019;184:266–277. doi: 10.1016/j.exer.2019.05.006
   PubMed Web of Science ®Google Scholar
• McMahon O, Hallam TM, Patel S, et al. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Hum Mol Genet. 2021;30(13):1188–1199. doi: 10.1093/hmg/ddab086
   PubMed Web of Science ®Google Scholar
• ESY N, Kady N, Hu J, et al. Membrane attack complex mediates retinal pigment epithelium cell death in stargardt macular degeneration. Cells. 2022;11(21):3462. doi: 10.3390/cells11213462
   PubMed Web of Science ®Google Scholar
• Mullins RF, Schoo DP, Sohn EH, et al. The membrane attack complex in aging human choriocapillaris. Am J Pathol. 2014;184(11):3142–3153. doi: 10.1016/j.ajpath.2014.07.017
   PubMed Web of Science ®Google Scholar
• Bora PS, Sohn J-H, Cruz JMC, et al. Role of complement and complement membrane attack complex in laser-induced choroidal Neovascularization1. J Immunol. 2005;174(1):491–497. doi: 10.4049/jimmunol.174.1.491
   PubMed Web of Science ®Google Scholar
• Nishiguchi KM, Yasuma TR, Tomida D, et al. C9-R95X polymorphism in patients with neovascular age-related macular degeneration. Invest Ophthalmol Visual Sci. 2012;53(1):508–512. doi: 10.1167/iovs.11-8425
   PubMed Web of Science ®Google Scholar
• Shughoury A, Ciulla TA, Bakall B, et al. Genes and gene therapy in inherited retinal disease. Int Ophthalmol Clin. 2021;61(4):3. doi: 10.1097/IIO.0000000000000377
   PubMedGoogle Scholar
• Khanani AM, Thomas MJ, Aziz AA, et al. Review of gene therapies for age-related macular degeneration. Eye. 2022;36(2):303–311. doi: 10.1038/s41433-021-01842-1
   PubMed Web of Science ®Google Scholar
• Ciulla T, Pennesi ME, Kiss S, et al. DNA- and RNA-based gene therapies in Ophthalmology. Int Ophthalmol Clin. 2021;61(3):3–16. doi: 10.1097/IIO.0000000000000359
   Google Scholar
• Tufts Office of the Vice Provost for Research. Preventing progression of dry age-related macular degeneration (AMD): Hemera Biosciences’ dry AMD drug succeeds in Phase I safety study [Internet]. Tufts University. 2020 [cited 2023 Apr 30]. Available from: https://viceprovost.tufts.edu/news/preventing-progression-dry-age-related-macular-degeneration-amd
   Google Scholar
• Sharma AK, Pangburn MK. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A. 1996;93(20):10996–11001. doi: 10.1073/pnas.93.20.10996
   PubMed Web of Science ®Google Scholar
• de Córdoba SR, Esparza-Gordillo J, de Jorge EG, et al. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41:355–367. doi: 10.1016/j.molimm.2004.02.005
   PubMed Web of Science ®Google Scholar
• Molins B, Fuentes-Prior P, Adán A, et al. Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. Sci Rep. 2016;6(1):22889. doi: 10.1038/srep22889
   PubMedGoogle Scholar
• Calippe B, Augustin S, Beguier F, et al. Complement factor H inhibits CD47-mediated resolution of inflammation. Immunity. 2017;46(2):261–272. doi: 10.1016/j.immuni.2017.01.006
   PubMed Web of Science ®Google Scholar
• Armento A, Honisch S, Panagiotakopoulou V, et al. Loss of complement factor H impairs antioxidant capacity and energy metabolism of human RPE cells. Sci Rep. 2020;10(1):10320. doi: 10.1038/s41598-020-67292-z
   PubMed Web of Science ®Google Scholar
• Borras C, Canonica J, Jorieux S, et al. CFH exerts anti-oxidant effects on retinal pigment epithelial cells independently from protecting against membrane attack complex. Sci Rep. 2019;9(1):13873. doi: 10.1038/s41598-019-50420-9
   PubMedGoogle Scholar
• Weismann D, Hartvigsen K, Lauer N, et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 2011;478(7367):76–81. doi: 10.1038/nature10449
   PubMed Web of Science ®Google Scholar
• Landowski M, Kelly U, Klingeborn M, et al. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. Proc Natl Acad Sci, USA. 2019;116(9):3703–3711. doi: 10.1073/pnas.1814014116
   PubMed Web of Science ®Google Scholar
• Zhan X, Larson DE, Wang C, et al. Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet. 2013;45(11):1375–1379. doi: 10.1038/ng.2758
   PubMed Web of Science ®Google Scholar
• Mulfaul K, Mullin NK, Giacalone JC, et al. Local factor H production by human choroidal endothelial cells mitigates complement deposition: implications for macular degeneration. J Pathol. 2022;257(1):29–38. doi: 10.1002/path.5867
   PubMed Web of Science ®Google Scholar
• Khanani AM, Maturi RK, Bagheri N, et al. A Phase I, single ascending dose study of GEM103 (recombinant human complement factor H) in patients with geographic atrophy. Ophthalmol Sci. 2022;2(2):100154. doi: 10.1016/j.xops.2022.100154
   PubMedGoogle Scholar
• Fridkis-Hareli M, Storek M, Mazsaroff I, et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases. Blood. 2011;118(17):4705–4713. doi: 10.1182/blood-2011-06-359646
   PubMed Web of Science ®Google Scholar
• Schnabolk G, Parsons N, Obert E, et al. Delivery of CR2-fH using AAV vector therapy as treatment strategy in the mouse model of choroidal neovascularization. Molecular Therapy-Methods Clin Devel. 2018;9:1–11. doi: 10.1016/j.omtm.2017.11.003
   PubMed Web of Science ®Google Scholar
• Rohrer B, Coughlin B, Bandyopadhyay M, et al. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther. 2012;28(4):402–409. doi: 10.1089/jop.2011.0212
   PubMed Web of Science ®Google Scholar
• Ellis S, Buchberger A, Holder J, et al. GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD). Invest Ophthalmol Visual Sci. 2020;61:2295.
   Web of Science ®Google Scholar
• Barratt J, Weitz I. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. 2021;12:712572. doi: 10.3389/fimmu.2021.712572
   PubMed Web of Science ®Google Scholar
• Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Trans Med. 2017;9(395):eaaf1443. doi: 10.1126/scitranslmed.aaf1443
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri Phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666–677. doi: 10.1001/jamaophthalmol.2018.1544
   PubMed Web of Science ®Google Scholar
• Boyer D, Rivera J, Ko Y-P, et al. Oral administration of the complement factor D inhibitor danicopan (ALXN2040) in preclinical studies demonstrates high and sustained drug concentrations in posterior ocular tissues for the potential treatment of geographic atrophy. Invest Ophthalmol Visual Sci. 2021;62:187.
   Web of Science ®Google Scholar
• Jaffe GJ, Sahni J, Fauser S, et al. Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD. Invest Ophthalmol Visual Sci. 2020;61:4305.
   Web of Science ®Google Scholar
• Grover A, Sankaranarayanan S, Mathur V, et al. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Ophthalmol Visual Sci. 2023;64(2):3. doi: 10.1167/iovs.64.2.3
   PubMed Web of Science ®Google Scholar
• Annexon Inc. Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function [Internet]. Annexon Biosci. 2023 [cited 2023 Aug 31]. Available from: https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic/.
   Google Scholar